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A novel human polyomavirus was identified with generic PCR in a kidney transplant patient under 
immunosuppressive treatment. Its genome was completely amplified and sequenced. In phylogenetic 
analyses it appeared as the closest relative to the African green monkey-derived lymphotropic 
polyomavirus (LPV). Further investigation of clinical samples from immunocompromised patients with 
specific nested PCR revealed additional positive samples indicating that the virus naturally infects 
humans. The virus was tentatively named Human Polyomavirus 9 (HPyV9). The previously observed 
seroreactivity to LPV in human populations might find a partial explanation in the circulation of HPyV9. 
 
 
Humans are known to be infected with a minimum of eight distinct polyomaviruses (PyVs): BK PyV 
(BKV (8)), JC PyV (JCV(14)), KI PyV (KIV (1)), WU PyV (WUV (9)), Merkel cell polyomavirus (MCPyV 
(6)), HPyV6 and HPyV7 (15) and Trichodysplasia spinulosa polyomavirus (TSV (17)). These members 
of the Polyomaviridae family are small DNA viruses which generally infect individuals in a persistent 
manner (from their early childhood on) but asymptomatically. In immunocompromised individuals, 
however, PyV reactivation has been associated with pathological conditions: JCV with progressive 
multifocal leukoencephalopathy, BKV with nephropathy and cystitis (both reviewed in: (12)), MCPyV 
with Merkel cell carcinoma (MCC), a rare but aggressive human tumor of the skin (6), and the 
Trichodysplasia spinulosa - associated virus (TSV) with the eponymous pathology (17). Given the 
growing disease burden entailed by acquired immunodeficiencies (mostly medically induced in 
industrialized countries, as well as a side effect of the spread of HIV-1 infections), human PyVs are 
now increasingly considered as emerging opportunistic pathogens. Gaining more insight into their 
diversity, prevalence and etiopathogenesis is therefore essential. Given the accelerated rate of human 
PyV discovery over the last few years it appears very likely that further, still unknown PyVs are actually 
circulating in human populations. In support of this notion, sero-epidemiological studies have revealed 
that up to 30% of human sera had strong reactions to antigens derived from a PyV initially identified in 
African green monkeys (Chlorocebus aethiops), the lymphotropic polyomavirus (LPV or AGMPyV) (4, 
10, 16, 18, 19), a fact which could not be explained by cross-reactivity to already known human PyVs 
(18). In addition, we recently identified m ore than 20 novel PyVs in a number of non human primates 
  
(NHP), including apes ((13) and N. Scuda, F. Leendertz and B. Ehlers,  unpublished data). These new 
PyVs nearly span the entire known diversity of mammalian PyVs, which suggests that primates as a 
whole, including humans, are infected with a plethora of PyVs. To further test this hypothesis, we 
screened DNA extracts from 597 clinical samples for the presence of PyVs. The majority of the 
samples were from immunocompromised transplant recipients, leukoencephalopathy (LEP) patients 
and HIV-positive patients (serum, plasma, urine or whole blood) that had originally been collected for 
BKV and herpes virus diagnostics at three German university hospitals (Table 1). In addition, 
cerebrospinal fluid (CSF) samples from LEP patients, bronchoalveolar lavage (BAL) from patients with 
pneumonia and fecal samples from children with diarrhoea were tested (Table 1). A generic PCR 
assay using degenerate and deoxyinosine-substituted primers was used as described previously (13). 
The primers had been designed to target conserved regions in the VP1 genes of the known PyVs 
(except the highly divergent PyV group represented by KIV, WUV, HPyV6 and HPyV7). From 85/597 
samples, VP1 sequences could be determined as shown by sequencing and BLAST analysis (2) in 
GenBank. All of these PyVs except one were known: BKV (n=56), JCV (n=18), MCPyV (n=8) and TSV 
(n=2) (Table 1). The PyV sequences were amplified from plasma (12/176), urine (71/179) and BAL 
(1/21) samples. CSF (n=74), whole blood (n=21), serum (n=87) and fecal (n=38) samples were 
negative (Table 1). Most importantly, an unknown PyV sequence was amplified from the serum of a 
kidney transplant patient under immunosuppressive treatment. In BLAST analysis it revealed the 
closest similarity to the VP1 gene of LPV (pairwise nucleic acid identity: 83%). To obtain additional 
sequence information of the novel PyV, a 950 bp genome fragment spanning parts of the VP3 and 
VP1 genes was amplified. For this purpose, two degenerate sense primers derived from the VP3 
sequence of LPV and two specific antisense primers deduced from the novel VP1 sequence were 
used in a nested PCR. Based on the resulting sequence, primers were designed tail-to-tail for the 
amplification and sequencing of the remaining part of the genome, and used in nested long-distance 
(LD-) PCR (all primer sequences and PCR reaction conditions are shown in Tables S1 and S2 of the 
supplemental material). A final circular genome of 5026 bp was obtained, and confirmed to be more 
similar to the LPV genome (pairwise nucleic acid identity: 76%) than to those of other PyVs (<60%). 
Since eight human PyVs are presently known, the virus from which the genome originated was 
tentatively named Human Polyomavirus 9 (HPyV9). Examination of putative open reading frames 
(ORFs) showed that the genome of HPyV9 has a typical PyV structure with an early region encoding 
regulatory proteins (small t and large T antigens) and a late region coding for structural proteins (VP1, 
VP2 and VP3) separated by a non-coding control region (NCCR) (Figure 1A). HPyV9 lacked any ORF 
encoding an agnoprotein. The ORF locations on the viral genome and their similarity to LPV and other 
human PyVs are listed in the Table S3 in the supplemental material. Over the entire genome length 
HPyV9 and LPV revealed a high similarity (see Figure S4 in the supplemental material) including 
functionally important sites in the NCCR and the large T and VP1 proteins (Figures 1B-1D, 
respectively). Phylogenetic analyses were performed using a concatenated dataset of VP1, VP2 and 
large T sequences including HPyV9 as well as a representative collection of published PyVs (Table S5 
of the supplemental material). Preparation of the dataset as well as downstream analyses, including 
maximum likelihood (ML) and Bayesian tree reconstructions were conducted as described previously 
(13). The resulting tree evidenced the close relationship of HPyV9 and LPV, which formed a highly 
supported monophyletic group - bootstrap (Bp) and posterior probability (pp) values: 100 and 1 (Figure 
2). To determine whether individuals other than the index case were infected with HPyV9, all 597 
samples were re-screened with HPyV9-specific nested PCR using primers deduced from the VP1 
sequence (see Tables S1 and S2 in the supplemental material). In four additional samples (serum, 
plasma, whole blood and urine), VP1 sequences of HPyV9 were detected (100% nucleic acid 
sequence identity to the index VP1 sequence). All CSF and BAL samples were negative (Table 1). In 
attempting to amplify complete genomes sequences from these samples, PyV genomes were pre-
amplified by using the Templiphi 100 rolling circle amplification kit, according to the instructions of the 
manufacturer (GE Healthcare, Germany), prior to perform the VP3/VP1-PCR and the LD-PCR. By this 
approach, another complete HPyV9 genome could be amplified (from the plasma sample of a renal 
transplant patient; data not shown). It revealed 100% nucleic acid identity to the index genome. These 
findings qualify HPyV9 as a human virus, however with a low prevalence in the selected samples (as 
revealed by DNA-based assays). Further studies are required to identify the sites of HPyV9 replication 
and persistence as well as to determine HPyV9 pathogenicity in immunocompetent and 
immunocompromised individuals. Notably, HPyV9 exhibited very close sequence relatedness to LPV, 
a fact that deserves closer attention. Sero-epidemiological studies have indeed revealed that up to 
30% of adult human sera contain antibodies against LPV (3, 4, 10, 16). Viscidi et al. studied the 
serological cross reactivity between BKV, JCV, SV40 and LPV capsids using enzyme immunoassays 
(EIA) based on virus-like particles. Their data indicated that LPV-reactive antibodies found in human 
sera could not be attributed to cross-reacting BKV or JCV antibodies (18). Based on competition 
assays, Kean et al. could exclude serological crossreactivity between VP1 proteins of LPV and 
  
MCPyV (10). Taken together, these results pointed at LPV having a serologically related human 
counterpart. The capsid protein VP1 is the major structural component of polyomavirus particles. It 
contains antigenic determinants and is involved in the interaction of PyVs with host cells through its 
outfacing loops. Therefore the similarity between the HPyV9 and LPV VP1 proteins, even in the highly 
variable loop regions (Figure 1D), is remarkable, and serological cross-reactivity appears as a 
reasonable possibility. This hypothesis is supported by the finding that cross-reactivity has been 
observed between VP1 capsomers of JCV and BKV on the one hand and SV40 on the other hand 
(10), despite the fact that SV40 VP1 is more distantly related to the JCV/BKV VP1 (pairwise amino 
acid sequence identities: 75% and 81%, respectively) than HPyV9 to LPV (87%). Against this line of 
argumentation stand two observations. First, WUV and KIV VP1 capsomers show no evidence of 
cross-reactivity, while their VP1 amino acid sequences are approximately as distant from each other 
as JCV/BKV from SV40 (10). Then, it was also shown that antibodies raised against one or the other 
strains of BKV could occasionally discriminate subgroups in neutralization assays (11) while the 
maximum VP1 genetic distance within BKV is largely outscored by the genetic distance between 
LPV/AGMPyV and HPyV9 VP1 (Figure S6 of the Supplementary Material). All in all, these contrasted 
results prevent any firm prediction of cross-reactivity that would be solely based on genetic make-up. 
However, we propose that HPyV9 could at least be considered one good candidate for the frequent 
LPV-like serological reactivity observed in human populations, acknowledging that other PyVs might 
be involved as well. Another good candidate PyV could be LPV itself whose short DNA fragments 
were recently detected in CSF and blood of AIDS patients as well as in blood of healthy subjects (5). 
Other authors analysed patients suffering from progressive multifocal leukoencephalopathy, and did 
not detect LPV while using specific primers (7). Our data do not provide evidence of LPV infection in 
immunocompromised patients either. If the prevalence of both HPyV9 and LPV infection in human 
populations can be confirmed to be at low levels, the existence of other antigenically related, yet 
unknown human PyVs must be postulated. Further investigation of this question, notably involving 
differential serological testing of HPyV9 and LPV, should clarify this issue. The genome sequence of 
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Tables and Figures 
 




a samples collected for BKV diagnosis 
b plasma with active cytomegalovirus infection 
c -: PCR-negative 
d samples collected for cytomegalovirus diagnosis 
e samples collected for herpesvirus diagnosis 
f 25-100μl eluate from 10-30 ml urine (n=27) or from 0,2 ml urine (n=11) 
g patient with a double infection (MCPyV + HPyV9) 
h patients under Tysabri® (natalizumab) therapy 





























Figure 1 Genome map of HPyV9 and comparison of encoded proteins with those of LPV. (A) 
Genome organization of HPyV9. Putative coding regions for VP1 to VP3, small T antigen, and large T 
antigen are marked by arrows. (B) Part of the non-coding control region (NCCR) of HPyV9 was 
aligned with that of LPV using ClustalW (as implemented in MacVector 10.6). Conserved regions are 
outlined and shaded. T-antigen binding elements (GAGGC or the complement GCCTC) are 
underlined. (C) Comparison of HPyV9 and LPV large T proteins. The CR1, J, RB-binding, ori-binding 
and Zn-Finger domains are underlined. (D) Comparison of VP1 proteins. VP1 loops are underlined. 
Identical amino acids (in bold type) are outlined and shaded, similarities (in bold type) are outlined 






Figure 2 Bayesian chronogram deduced from the analysis of a 687 amino acid alignment of 
concatenated VP1, VP2 and large T sequences. PyVs identified from human hosts are in red, from 
non-human primates in blue. The clade formed by HPyV9 and LPV is highlighted by grey line color. 
Statistical support for branch is given where Bp≥70 and pp≥0.95. Bp values are shown after the slash 
bar, pp values before the slash bar. The scale axis is in amino acid substitution per site. This 
chronogram was rooted using a relaxed clock. A maximum likelihood analysis of the same dataset 
concluded to a similar topology and is thus not shown here. 
 
 
 
  
